San Francisco Bay Area
Leading and developing studies evaluating novel treatments in oncology. Development lead for the tobemstomig (PD1-LAG3 bispecific) program and cross-indication immunotherapy in late stage oncology. Filing lead for atezolizumab SC formulation.
Representing clinical scientists and medical directors in PDOH, and working with PDOH and SSF site leadership to build community at Genentech.
Leading and developing studies evaluating novel treatments for patients with GU cancers.
Practicing medicine and research in cancer immunology and immunotherapy
Physician Scientist Track, Internal Medicine
Combined MD PhD program at McGill University